Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials

• Published in: The journal of pathology. Clinical research Vol. 10; no. 5; pp. e12395 - n/a
• Main Authors: Pulaski, Hanna, Mehta, Shraddha S, Manigat, Laryssa C, Kaufman, Stephanie, Hou, Hypatia, Nalbantoglu, ILKe, Zhang, Xuchen, Curl, Emily, Taliano, Ross, Kim, Tae Hun, Torbenson, Michael, Glickman, Jonathan N, Resnick, Murray B, Patel, Neel, Taylor, Cristin E, Bedossa, Pierre, Montalto, Michael C, Beck, Andrew H, Wack, Katy E
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.09.2024; Wiley
• Subjects: Accuracy; Biopsy; Clinical medicine; Clinical trials; Clinical Trials as Topic; digital pathology; Disease management; Enrollments; Fatty liver; FDA approval; Humans; Image Interpretation, Computer-Assisted - methods; Inflammation; Liver - pathology; Liver diseases; Liver transplants; MASH; metabolic‐associated steatohepatitis; Metabolism; NASH; Non-alcoholic Fatty Liver Disease - pathology; nonalcoholic steatohepatitis; Observer Variation; Original; Pathology; Quality standards; Reproducibility of Results; Steatosis; validation; nonalcoholic steatohepatitis; metabolic‐associated steatohepatitis; digital pathology; MASH; clinical trials; NASH; validation
• ISSN: 2056-4538; 2056-4538
• DOI: 10.1002/2056-4538.12395

The gold standard for enrollment and endpoint assessment in metabolic dysfunction‐associated steatosis clinical trials is histologic assessment of a liver biopsy performed on glass slides. However, obtaining the evaluations from several expert pathologists on glass is challenging, as shipping the slides around the country or around the world is time‐consuming and comes with the hazards of slide breakage. This study demonstrated that pathologic assessment of disease activity in steatohepatitis, performed using digital images on the AISight whole slide image management system, yields results that are comparable to those obtained using glass slides. The accuracy of scoring for steatohepatitis (nonalcoholic fatty liver disease activity score ≥4 with ≥1 for each feature and absence of atypical features suggestive of other liver disease) performed on the system was evaluated against scoring conducted on glass slides. Both methods were assessed for overall percent agreement with a consensus “ground truth” score (defined as the median score of a panel of three pathologists’ glass slides). Each case was also read by three different pathologists, once on glass and once digitally with a minimum 2‐week washout period between the modalities. It was demonstrated that the average agreement across three pathologists of digital scoring with ground truth was noninferior to the average agreement of glass scoring with ground truth [noninferiority margin: −0.05; difference: −0.001; 95% CI: (−0.027, 0.026); and p < 0.0001]. For each pathologist, there was a similar average agreement of digital and glass reads with glass ground truth (pathologist A, 0.843 and 0.849; pathologist B, 0.633 and 0.605; and pathologist C, 0.755 and 0.780). Here, we demonstrate that the accuracy of digital reads for steatohepatitis using digital images is equivalent to glass reads in the context of a clinical trial for scoring using the Clinical Research Network scoring system.